Daxor Corporation news
Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces five new hospitals have implemented the Company’s BVA-100 blood volume diagnostic for clinical use to guide fluid management in heart failure patients during the first quarter of 2023. The addition of these hospitals contributes to the significant growth of blood volume ana
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new pilot randomized control trial (RCT) data from Duke Heart validating the greater accuracy of the Company’s BVA-100 diagnostic in optimizing decongestion therapy for heart failure patients and pointed to a strong signal toward reducing hospital length of stay in a pilot cohort of 31 patients.
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. Data were presented at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-ba
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the appointment of Linda Cooper as Vice President of Project Management.
“Linda joins Daxor with over 30 years of experience in product development and commercialization in the medical device industry. Linda’s proven track record makes her an excellent addition to t
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces joining the Heart Failure Society of America (HFSA) as a corporate member to collaborate and deepen engagement with leaders in the field of heart failure.
“The HFSA is the premier society focused on improving Heart Failure outcomes, a condition that more than 6 million Am
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a new study in the Journal of Cardiovascular Translational Research that examined pressure-volume profiles in heart failure patients using Daxor’s BVA-100 blood test to measure intravascular volume overload compared to a commercially avai
DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the closing of its previously announced
DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the pricing of an underwritten public of
DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced that it has commenced an underwritten pu
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces Daxor’s BVA-100 diagnostic will be featured in a MedAxiom Academy webinar – Best Practices for Using Blood Volume Analysis to Reduce Heart Failure LOS, Readmissions, Mortality and Costs on November 17, 2022, at 1pm ET. This live webinar will take a deep dive into the best practices for implementing the innovative diagnostic BVA which has been shown to improv